AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Thursday 5 November 2026
News from the 24 hours to Thursday morning, 5 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Most coverage concerned reports that AstraZeneca offered $10 billion to buy Rhythm, a maker of obesity drugs, which was viewed as a strategic expansion. Strong third-quarter growth, unchanged guidance and regulatory acceptances added support, while a withdrawn EU application was a minor negative.
What drove it
- Rhythm takeover bid
- Q3 results and guidance
- lung cancer filings
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Fri 30 Oct | +6.3 | 13 |
| Sat 31 Oct | +8.7 | 78 |
| Sun 1 Nov | +6.3 | 8 |
| Mon 2 Nov | +9.2 | 15 |
| Tue 3 Nov | +7.5 | 28 |
| Wed 4 Nov | +5.0 | 19 |
| Thu 5 Nov | +6.3 | 24 |
7 stories · 24 headlines · strongest first
Pharma and healthcare on 5 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca reportedly offers $10bn for Rhythm Pharmaceuticals +4.514 headlines today · WSJ reported AstraZeneca made a $10bn offer for Rhythm, whose shares jumped about 28%. | ||
| +5.5 | Bid framed as strategic move into rare obesity treatments. | |
| +5.0 | Reuters sources confirm big approach to obesity drug company. | |
| +5.0 | Original report of large offer for Rhythm. | |
| +5.0 | Large acquisition approach expanding obesity and rare disease pipeline. | |
| +5.0 | Report of sizeable offer for obesity-focused drugmaker. | |
| +5.0 | Syndicated report of large offer for obesity drugmaker. | |
| +5.0 | Another report of large offer for Rhythm. | |
| +5.0 | Another report of large offer for Rhythm. | |
| +4.7 | Possible large purchase; target's shares rose sharply. | |
| +4.5 | Considering sizeable bid for obesity-focused rival. | |
| +3.3 | Target stock rally driven by AstraZeneca approach. | |
| +3.3 | Target shares jump on reported approach from AstraZeneca. | |
| +3.3 | Target jumps on reported approach from AstraZeneca. | |
| +3.3 | Target shares jump on reported approach from AstraZeneca. | |
| AstraZeneca Q3 results and $1.5bn savings plan +7.14 headlines today · 88 in all, since 31 October · Pieces cover AstraZeneca's Q3 beat, reconfirmed guidance and cost-savings reset. | ||
| +9.2 | Earnings ahead of expectations and guidance reaffirmed. | |
| +8.3 | Strong quarterly growth supports unchanged full-year expectations. | |
| +8.3 | Robust quarter and unchanged guidance. | |
| +7.5 | Shares rose after cost-saving changes. | |
| AstraZeneca lung cancer combination filings accepted +6.22 headlines today · 7 in all, since 2 November · Regulators in both Europe and Japan have accepted filings for a lung cancer drug combination. | ||
| +7.5 | Regulators in two regions accepted lung cancer submissions. | |
| +6.7 | Regulatory acceptances advance lung cancer combination. | |
| AstraZeneca drops EU Truqap prostate cancer bid −5.81 headline today · AstraZeneca withdrew its EU application for Truqap in PTEN-deficient prostate cancer. | ||
| −5.8 | Withdrew European application for prostate cancer indication. | |
| AstraZeneca invested $2.0bn in ivonescimab programme +4.21 headline today · SMMT disclosed AstraZeneca's $2.0bn investment as the ivonescimab programme expanded. | ||
| +4.2 | Investment in partner's lung cancer drug programme progressing. | |
| AstraZeneca valuation after oncology wins +3.31 headline today · A piece asks whether AstraZeneca is fully priced. | ||
| +3.3 | Valuation question after oncology successes; mildly positive. | |
| AstraZeneca India names new managing director +1.71 headline today · 4 in all, since 4 November · AstraZeneca appointed Naveen Krishna Yamarthi to lead India operations. | ||
| +1.7 | Routine leadership appointment for Indian business. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.